Halozyme Therapeutics (HALO) Interest Coverage Ratio Growth (1y) (2014 - 2026)
Halozyme Therapeutics (HALO) Interest Coverage Ratio Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | -347.04% |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - | 73.00% |
| 10 | Halozyme Therapeutics | 9.76 Bn | 9.44 Bn | 297.47 Mn | 7.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.10% |
| Dec 31, 2025 | -71.31% |
| Sep 30, 2025 | -83.36% |
| Jun 30, 2025 | 77.79% |
| Mar 31, 2025 | 47.55% |
| Dec 31, 2024 | 41.91% |
| Sep 30, 2024 | 84.09% |
| Jun 30, 2024 | 23.29% |
| Mar 31, 2024 | 79.00% |
| Dec 31, 2023 | 67.08% |
| Sep 30, 2023 | 76.78% |
| Jun 30, 2023 | 91.55% |
| Mar 31, 2023 | -72.47% |
| Dec 31, 2022 | -40.74% |
| Sep 30, 2022 | -74.28% |
| Jun 30, 2022 | -79.34% |
| Mar 31, 2022 | 66.61% |
| Dec 31, 2021 | 78.48% |
| Sep 30, 2021 | 433.60% |
| Jun 30, 2021 | 799.20% |